Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DT1R9E
|
|||
| Drug Name |
REGN5668
|
|||
| Drug Type |
Bispecific antibody
|
|||
| Indication | Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 1/2 | [1] | |
| Company |
Regeneron Tarrytown, NY
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04590326) Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3). U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.